This is a transformative reverse merger that hands control of the public entity to Slate Medicines. FULC shareholders face massive dilution as Slate's valuation dwarfs Fulcrum's, but receive a pre-closing cash dividend of excess net cash. The combined company will have a new pipeline and ~$245M in fresh capital. Monitor the shareholder vote and HSR clearance timeline. The deal effectively makes FULC a new biotech with Slate's programs.
Price Chart
Executive Summary
Fulcrum Therapeutics (FULC) entered into a definitive merger agreement to acquire Slate Medicines in a reverse-merger transaction. Fulcrum will issue shares to Slate stockholders at an exchange ratio based on a $350M company valuation (plus a concurrent $245M PIPE investment), while Fulcrum is valued at $31.3M. The combined company will operate as Slate Medicines, with Slate's management taking control. Fulcrum stockholders will receive a pre-closing cash dividend of excess net cash above $20.3M. The deal requires shareholder approval and HSR clearance, with a February 28, 2027 outside date. This is a transformative event that effectively hands control to Slate, making FULC a new entity with a new pipeline and substantial cash from the PIPE.
Key Financial Metrics
Key Facts
- Fulcrum Therapeutics to acquire Slate Medicines via reverse merger; Slate valued at $350M pre-money, Fulcrum at $31.3M.
- Concurrent $245M PIPE investment from institutional investors at Slate's pre-money valuation.
- Fulcrum stockholders to receive a pre-closing cash dividend of excess net cash above $20.3M target.
- Combined company to be renamed Slate Medicines, with Slate's management and board taking control.
- Fulcrum CEO Alex Sapir and CFO Alan Musso will depart; Slate CEO Gregory Oakes to lead combined entity.
- Fulcrum's existing pipeline (losmapimod) is effectively being wound down; combined entity will focus on Slate's programs.
- Deal requires Fulcrum stockholder approval for share issuance and reverse stock split; HSR waiting period must expire.
- Fulcrum's VP of Finance Greg Tourangeau departed 7 days prior to deal announcement, replaced by CFO Musso.
Financial Impact
Reverse merger values Slate at $350M pre-money plus $245M PIPE = $595M total; Fulcrum valued at $31.3M. Combined entity will have Slate's pipeline and substantial cash from PIPE.
Risk Factors
- Shareholder vote may fail; Fulcrum's 0% analyst bullish consensus suggests potential opposition.
- HSR review could delay or block the transaction.
- Integration risk: Fulcrum's losmapimod program is being wound down; combined entity's pipeline is unproven.
- Pre-closing cash dividend reduces cash available to combined company; net cash at closing must be ≥ $0 after dividend.
- Fulcrum's historical performance shows poor stock returns; this deal represents a complete strategic pivot.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-353278 |
| Document: d136791dex104.htm | 0001193125-26-353278 |
| Document: d136791dex105.htm | 0001193125-26-353278 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | S-4 | $3.85 $3.70 | ▲ +3.90% | ▲ +3.57% | $3.67 (+4.68%) |
Aug 17, 2026 6w ago | 425 | $3.84 $3.78 | ▲ +1.56% | ▼ −0.42% | $3.67 (+4.43%) |
Aug 17, 2026 6w ago | 425 | $3.84 $3.78 | ▼ −1.56% | ▲ +0.42% | $3.67 (−4.43%) |
Aug 17, 2026 6w ago | 8-K | $3.84 $3.78 | ▼ −1.56% | ▲ +0.42% | $3.67 (−4.43%) |
Aug 17, 2026 6w ago | Press Release | $3.84 $3.78 | ▼ −1.56% | ▲ +0.42% | $3.67 (−4.43%) |
Aug 10, 2026 7w ago | 8-K | $3.75 $3.82 | ▲ +1.87% | ▲ +2.78% | $3.67 (−2.13%) |
Jul 15, 2026 11w ago | 3 | $3.50 $3.71 | ▲ +6.00% | ▲ +2.38% | $3.67 (+4.86%) |
Jun 11, 2026 16w ago | Institutional Cluster | $3.55 $3.59 | ▲ +1.13% | ▼ −0.76% | $3.67 (+3.38%) |
Apr 27, 2026 22w ago | 8-K | $7.72 $6.76 | ▼ −12.44% | ▼ −17.39% | $3.67 (−52.46%) |
Apr 27, 2026 22w ago | Press Release | $7.72 $6.76 | ▼ −12.44% | ▼ −17.39% | $3.67 (−52.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access